ABSTRACT
Digital papillary adenocarcinoma (DPAc) is a rare, aggressive cutaneous malignancy of sweat gland derivation. Herein, we conduct a retrospective study of 213 DPAc patients using the 17 registries of the Surveillance, Epidemiology, and End Results (SEER) program. We estimate the incidence of DPAc to be 0.11 per million persons per year, with the incidence rising over the past two decades. Our study shows DPAc to most commonly afflict White males, typically in their 40s-60s. We note a 5-year disease-specific survival of 98.3% and 5-year overall survival of 95.7%. We also show advanced age to be associated with more aggressive disease and identify tumor size as an independent risk factor impacting disease-specific survival. Our results also suggest that patients with DPAc have an elevated risk of developing subsequent primary malignancies, with males being at increased risk of developing lung/bronchial neoplasms and females being at increased risk of developing breast cancer.
ABSTRACT
BACKGROUND: Although lidocaine is widely used in dermatologic surgery, no formal standard concentration is established. Previous research indicates that more dilute concentrations may offer equally effective anesthesia while potentially reducing toxicity risks. In addition, diluting commercially available lidocaine conserves supplies-a significant benefit during periods of lidocaine shortage. OBJECTIVE: To evaluate the efficacy of 0.25% lidocaine compared with that of 0.5% lidocaine in achieving anesthesia in cutaneous surgery. MATERIALS AND METHODS: A prospective, double-blind study with 100 patients undergoing cutaneous surgery (Mohs surgery or excision) randomized to receive either 0.25% or 0.5% lidocaine for their percutaneous anesthesia. Patients completed a postoperative survey assessing pain level, satisfaction, and willingness to undergo future dermatologic surgery. RESULTS: This study revealed no statistically significant differences between the 0.25% and 0.5% lidocaine groups regarding pain scores, patient satisfaction, total lidocaine volume, rescue lidocaine volume, or willingness to undergo the procedure again. CONCLUSION: 0.25% lidocaine is a safe and effective option for achieving anesthesia during Mohs surgery and standard excisions. The results suggest that 0.25% lidocaine can be used to optimize high-value care and enhance patient safety in dermatologic surgery.
Subject(s)
Carcinoma, Merkel Cell , Comorbidity , Skin Neoplasms , Humans , Carcinoma, Merkel Cell/epidemiology , Carcinoma, Merkel Cell/diagnosis , Retrospective Studies , Male , Skin Neoplasms/epidemiology , Skin Neoplasms/diagnosis , Female , Aged , Case-Control Studies , Middle Aged , Aged, 80 and over , Risk FactorsSubject(s)
Carcinoma, Merkel Cell , Databases, Factual , Skin Neoplasms , Humans , Carcinoma, Merkel Cell/mortality , Carcinoma, Merkel Cell/epidemiology , Carcinoma, Merkel Cell/pathology , Carcinoma, Merkel Cell/diagnosis , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Skin Neoplasms/epidemiology , Male , Female , Aged , Databases, Factual/statistics & numerical data , Aged, 80 and over , Middle Aged , Cause of DeathABSTRACT
Introduction Merkel cell carcinoma is an aggressive neuroendocrine tumor that is related to immunosuppression and the Merkel cell polyomavirus. It is more common on the head and neck and has been associated with other skin malignancies such as basal cell carcinoma, squamous cell carcinoma, and melanoma. However, there has never been a nationwide investigation that quantifies Merkel cell carcinoma's connection with these subgroups. Methods Utilizing the National Institutes of Health's All of Us open-access database, a retrospective study was conducted by filtering for Merkel cell carcinoma through the International Classification of Diseases, 9th and 10th Clinical Modification codes 209.* and C4A.*, respectively. This led to the inclusion of 41 patients in the study, with each instance compared to four control patients without merkel cell carcinoma, matched by age, race, and gender. The data's demographics and skin cancer co-morbidities were collected and evaluated with odds ratios and 95% confidence intervals using Wald's method. Results In patients with merkel cell carcinoma, a statistically significant gradient of increasing risk for developing basal cell carcinoma (Odds Ratio, 11.63; 95% Confidence Interval, 4.30-31.45; P < 0.0001), squamous cell carcinoma (Odds Ratio, 15.09; 95% Confidence Interval, 3.87-58.84; P = 0.0001), and melanoma (Odds Ratio, 27.94; 95% Confidence Interval, 3.26-239.48; P = 0.0024) was observed. The race/ethnicity demographics showed that 85.4% of the patients were white, and they were at the highest risk of developing merkel cell carcinoma. However, the study has limitations, such as the inability to identify the stage of merkel cell carcinoma among patients and the lack of consideration for other confounding variables. Conclusion The study examines the link between merkel cell carcinoma and other skin malignancies, underscoring the need for more national research to better understand the underlying causes that contribute to this link. The findings also indicate the possibility of sample bias in the All of Us database, emphasizing the need to assess the patient population's representativeness in such investigations.
Subject(s)
Dermatofibrosarcoma , Neoplasms, Second Primary , SEER Program , Skin Neoplasms , Humans , Dermatofibrosarcoma/epidemiology , Dermatofibrosarcoma/pathology , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , SEER Program/statistics & numerical data , Retrospective Studies , Male , Female , Adult , Middle Aged , Neoplasms, Second Primary/epidemiology , Young Adult , Adolescent , United States/epidemiology , Aged , Risk Assessment/statistics & numerical data , Child , Risk FactorsSubject(s)
Hemochromatosis , Skin Neoplasms , Humans , Hemochromatosis/genetics , Hemochromatosis/complications , Case-Control Studies , Skin Neoplasms/genetics , Skin Neoplasms/epidemiology , Male , Female , Middle Aged , Aged , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/genetics , Carcinoma, Squamous Cell/genetics , AdultSubject(s)
Mohs Surgery , Skin Neoplasms , Humans , Mohs Surgery/adverse effects , Antibiotic Prophylaxis , Skin Neoplasms/surgerySubject(s)
Diabetes Mellitus, Type 2 , Dyslipidemias , Granuloma Annulare , Hypertension , Humans , Granuloma Annulare/diagnosis , Granuloma Annulare/complications , Granuloma Annulare/pathology , Dyslipidemias/complications , Diabetes Mellitus, Type 2/complications , Hypertension/complications , Hypertension/etiologyABSTRACT
Pityriasis rubra pilaris (PRP) is a rare papulosquamous reaction pattern with a significant impact on quality of life. Type I PRP is the most common PRP variant, presenting as erythematous papules emerging in a follicular distribution and later coalescing into plaques with characteristic islands of sparing; histologically, an alternating pattern of orthokeratosis and parakeratosis is considered the hallmark of PRP (checkerboard hyperkeratosis). Other PRP variants (types II-V) differ in their age of onset and clinical presentation. Type VI PRP is a rare PRP subtype associated with human immunodeficiency virus infection and is occasionally associated with diseases of the follicular occlusion tetrad. Caspase recruitment domain family, member 14 (CARD14)-associated papulosquamous eruption and facial discoid dermatitis are newly described disease states that have an important clinical overlap with PRP, creating shared conundrums with respect to diagnosis and treatment. The etiology inciting PRP often remains uncertain; PRP has been suggested to be associated with infection, malignancy, or drug/vaccine administration in some cases, although these are based on case reports and causality has not been established. Type V PRP is often due to inborn CARD14 mutations. Furthermore, recent literature has identified interleukin-23/T-helper-17 cell axis dysregulation to be a major mediator of PRP pathogenesis, paving the way for mechanism-directed therapy. At present, high-dose isotretinoin, ixekizumab, and secukinumab are systemic agents supported by single-arm prospective studies; numerous other agents have also been trialed for PRP, with variable success rates. Here, we discuss updates on clinical manifestations, present new insights into etiopathogenesis, and offer a survey of recently described therapeutic options.